Identification of new fisetin analogs as kinase inhibitors: Data on synthesis and anti-skin cancer activities evaluation
Tithi Roy,
Samuel T. Boateng,
Sergette Banang-Mbeumi,
Pankaj K. Singh,
Pratik Basnet,
Roxane-Cherille N. Chamcheu,
Federico Ladu,
Isabel Chauvin,
Vladimir S. Spiegelman,
Ronald A. Hill,
Konstantin G. Kousoulas,
Bolni Marius Nagalo,
Anthony L. Walker,
Jean Fotie,
Siva Murru,
Mario Sechi,
Jean Christopher Chamcheu
Affiliations
Tithi Roy
School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana - Monroe, Monroe, LA 71209-0497, USA
Samuel T. Boateng
School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana - Monroe, Monroe, LA 71209-0497, USA
Sergette Banang-Mbeumi
School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana - Monroe, Monroe, LA 71209-0497, USA
Pankaj K. Singh
Department of Chemistry and Pharmacy, University of Sassari, Via Vienna 2, 07100 Sassari, Italy; Corresponding author(s).
Pratik Basnet
School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana - Monroe, Monroe, LA 71209-0497, USA; Chemistry, School of Sciences, University of Louisiana at Monroe, Monroe, LA 71209-0497, USA
Roxane-Cherille N. Chamcheu
School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana - Monroe, Monroe, LA 71209-0497, USA
Federico Ladu
Department of Chemistry and Pharmacy, University of Sassari, Via Vienna 2, 07100 Sassari, Italy
Isabel Chauvin
Chemistry, School of Sciences, University of Louisiana at Monroe, Monroe, LA 71209-0497, USA
Vladimir S. Spiegelman
Department of Pediatrics, Division of Pediatric Hematology/Oncology, Pennsylvania State University College of Medicine, Milton S. Hershey Medical Center, Hershey, Pennsylvania 17033-0850, USA
Ronald A. Hill
School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana - Monroe, Monroe, LA 71209-0497, USA
Konstantin G. Kousoulas
Division of Biotechnology and Molecular Medicine, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA; Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA
Bolni Marius Nagalo
Division of Hematology and Medical Oncology, Mayo Clinic Hospital, Phoenix, AZ, 85054, USA
Anthony L. Walker
School of Clinical Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71209-0497, USA
Jean Fotie
Department of Chemistry and Physics, Southeastern Louisiana University, Hammond, LA 70402-0878, USA
Siva Murru
Chemistry, School of Sciences, University of Louisiana at Monroe, Monroe, LA 71209-0497, USA; Corresponding author(s).
Mario Sechi
Department of Chemistry and Pharmacy, University of Sassari, Via Vienna 2, 07100 Sassari, Italy
Jean Christopher Chamcheu
School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana - Monroe, Monroe, LA 71209-0497, USA; Corresponding author(s).
This article contains supplemental datasets of the recently published related research article “Synthesis, Inverse Docking-Assisted Identification and in vitro Biological Characterization of Flavonol-based Analogs of Fisetin as c-Kit, CDK2 and mTOR Inhibitors against Melanoma and Non-melanoma Skin Cancers” by Roy et al., [1]. It provides in-depth data not included in the original co-submission on the biophysical, molecular docking, and biological characterization of newly synthesized flavonol-based analogs of fisetin, a natural dietary small molecule with anticancer and anti-inflammatory properties. These synthetic small molecules were investigated as new, potential single and/or multi-kinase inhibitors of the cyclin-dependent kinase-2 (CDK2), receptor tyrosine kinases (c-KITs), and mammalian targets of rapamycin (mTOR) targets, potentially active against melanoma or non-melanoma skin cancers. Furthermore, this data-in-brief article comprises additional sets of results on several aspects of the properties of the dual and multiple kinase inhibitor compounds’ effects that were not presented in the associated article, including the activated targets that are dysregulated in skin cancers; the effects on markers of apoptosis; on colony formation; and in scratch wound healing assays. The study has identified a panel of novel fisetin analogs that are either single- or multi-kinase inhibitors, which may be further developed as active for the treatment of melanoma and non-melanoma skin cancers. The dataset presented herein will be utilized for additional studies aiming to establish a biological platform to steer for predictive and experimental screening of novel flavonoids and analogs in relevant organoids, humanized animal models and in vivo disease models. The present results should also serve as a key stepping-stone towards enabling target-structure-based design, synthesis and initial testing of novel analogs or derivatives of fisetin. The current study may eventually lead to the development of safe, promising and preclinical candidate entities for treatment of skin and other forms of cancers as well as various other human diseases, which can possibly add to the general armamentarium of promising and safe drugs for health promotion.
